Publikationer pr. år
Publikationer pr. år
Emil Aagaard Thomsen, Anne Bruun Rovsing, Mads Valdemar Anderson, Hanne Due, Jinrong Huang, Yonglun Luo, Karen Dybkær, Jacob Giehm Mikkelsen*
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review
Diffuse large B-cell lymphoma (DLBCL) is characterized by extensive genetic heterogeneity, and this results in unpredictable responses to the current treatment, R-CHOP, which consists of a cancer drug combination supplemented with the humanized CD20-targeting monoclonal antibody rituximab. Despite improvements in the patient response rate through rituximab addition to the treatment plan, up to 40% of DLBCL patients end in a relapsed or refractory state due to inherent or acquired resistance to the regimen. Here, we employ a lentiviral genome-wide clustered regularly interspaced short palindromic repeats library screening approach to identify genes involved in facilitating the rituximab response in cancerous B cells. Along with the CD20-encoding MS4A1 gene, we identify genes related to B-cell receptor (BCR) signaling as mediators of the intracellular signaling response to rituximab. More specifically, the B-cell linker protein (BLNK) and Bruton's tyrosine kinase (BTK) genes stand out as pivotal genes in facilitating direct rituximab-induced apoptosis through mechanisms that occur alongside complement-dependent cytotoxicity (CDC). Our findings demonstrate that rituximab triggers BCR signaling in a BLNK- and BTK-dependent manner and support the existing notion that intertwined CD20 and BCR signaling pathways in germinal center B-cell-like-subtype DLBCL lead to programmed cell death.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Molecular Oncology |
Vol/bind | 14 |
Udgave nummer | 9 |
Sider (fra-til) | 1978-1997 |
Antal sider | 20 |
ISSN | 1574-7891 |
DOI | |
Status | Udgivet - 1 sep. 2020 |
Publikation: Ph.d.-afhandling